학술논문
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
Document Type
Article
Author
Source
In: The Lancet . (The Lancet, 1 October 2022, 400(10358):1103-1116)
Subject
Language
English
ISSN
1474547X
01406736
01406736